|
WO2021041082A1
|
|
Performing segmentation based on tensor inputs
|
|
WO2020205100A1
|
|
Recombinant eril-15 nk cells
|
|
TW202038975A
|
|
Combination therapies for multiple myeloma
|
|
US2020046817A1
|
|
Neoepitope vaccine and immune stimulant combinations and methods
|
|
WO2020077180A1
|
|
Treatment of immunosuppressed subjects
|
|
WO2020073045A1
|
|
Cd40 and cd40l combo in an adenovirus vaccine vehicle
|
|
WO2021071468A1
|
|
Neoepitope vaccine and immune stimulant combinations and methods
|
|
WO2020061203A1
|
|
Methods and compositions for modulating myeloid-derived suppressor cells
|
|
WO2020041561A1
|
|
Assessing microsatellite instability by liquid biopsy
|
|
WO2020018425A1
|
|
Antibody-dependent cell-mediated toxicity mediated by alt-803 and neo-201
|
|
US2019381141A1
|
|
Hiv treatment compositions and methods
|
|
US2019358201A1
|
|
Modified doxorubicin compositions and methods
|
|
TW202003030A
|
|
Neoepitope vaccine and immune stimulant combinations and methods
|
|
WO2019147921A1
|
|
Rapid verification of virus particle production for a personalized vaccine
|
|
CN111836639A
|
|
Compositions and methods for combination cancer vaccine and immune adjuvant therapy
|
|
US2020354730A1
|
|
Improved Yeast Polytope Vaccine Compositions And Methods
|
|
CN111417648A
|
|
Multivalent antigens stimulating TH1 and TH2
|
|
CA3077352A1
|
|
Lipid-based antigens and t-cell receptors on nk cells
|
|
AU2018338786A1
|
|
Antigenic proteins and methods therefor
|
|
AU2018338874A1
|
|
Cd1d and tcr-nkt cells
|
